Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to firstname.lastname@example.org so that we can defer those challenges. Your health and safety are paramount to us.
Posted 26 November 2012 | By Ansis Helmanis,
The European Commission has opened a consultation on the time needed by companies to implement product packaging changes under the new EU pharmacovigilance law.
Under that legislation, companies are required to incorporate a black symbol on certain drug products subject to additional monitoring because of their specific safety profile.
The Commission is considering the need for phasing in the black symbol in the summary of product characteristics (SmPC) and the package leaflet of products.
The concept paper for public consultation invites stakeholders to comment on how much time a marketing authorization holder needs to adapt and print the updated product information (summary of product characteristics and patient leaflet. Comments must be submitted by 10 January 10 2013.
Read all Breaking News from RegLink
Tags: European Commission, EU
Regulatory Focus newsletters
All the biggest regulatory news and happenings.